Evidence map›Paper›PMID 38218744›Full record

SynthesisRheumatology (Oxford, England)2024

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.

Philip J Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, Laura C Coates

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 6 countries.

Philip J MeaseSwedish Medical Center and Providence St. Joseph Health, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6620-0457
Dafna D GladmanSchroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, ON, Canada.
Joseph F MerolaDepartment of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Peter NashSchool of Medicine, Griffith University, Brisbane, QLD, Australia.ORCID 0000-0002-2571-788X
Stacy GrieveDepartment of RWA Health Economics, Cytel, Inc, Waltham, MA, USA.
Victor Laliman-KharaDepartment of RWA Health Economics, Cytel, Inc, Waltham, MA, USA.
Damon WillemsUCB Pharma, Brussels, Belgium.
Vanessa TaiebUCB Pharma, Colombes, France.
Adam R PrickettUCB Pharma, Slough, UK.
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK.ORCID 0000-0002-4756-663X
Cytel (United States) · USBrigham and Women's Hospital · USGriffith University · AUProvidence College · USUCB Pharma (Belgium) · BEUCB Pharma (France) · FRUCB Pharma (United Kingdom) · GBUniversity Health Network · CAUniversity of Oxford · GB

Funding

AbbVieUCB Pharma
6 · The paper itself

Abstract

objectivesTo understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA).

methodsA systematic literature review (most recent update conducted on 1 January 2023) identified randomized controlled trials (RCTs) of b/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12-24 for b/tsDMARD-naïve and TNF inhibitor (TNFi)-experienced patients. Safety at Weeks 12-24 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank.

resultsThe NMA included 41 RCTs for 22 b/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b/tsDMARD-naïve patients and 2nd in TNFi-experienced patients. In b/tsDMARD-naïve patients, bimekizumab ranked 6th, 5th and 3rd for ACR response ACR20/50/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd and 1st for ACR20/50/70, respectively. For Psoriasis Area and Severity Index 90/100, bimekizumab ranked 2nd and 1st in b/tsDMARD-naïve patients, respectively, and 1st and 2nd in TNFi-experienced patients, respectively. Bimekizumab was comparable to b/tsDMARDs for serious adverse events.

conclusionBimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticAntibodies, Monoclonal, HumanizedHumansRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, Monoclonal, HumanizedAntirheumatic AgentsbimekizumabACRbimekizumabdisease-modifying antirheumatic drugsMDAnetwork meta-analysisPASIpsoriatic arthritissystematic literature review

Identifiers

PMID38218744
PMCPMC11215990
OpenAlexW4390849402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.